Oklo Stock Jumps 5% as Subsidiary Clears First Regulatory Hurdle – Time to Buy?

TLDR

• Oklo’s subsidiary Atomic Alchemy received its first-ever NRC materials license, allowing it to handle, process, and distribute isotopes from its Idaho lab.
• The license enables initial commercial sales from the Idaho Radiochemistry Laboratory, opening a new revenue stream for the pre-revenue company.
• The license is not for Oklo’s main advanced nuclear reactors — those still await NRC approval before any electricity can be sold.
• Oklo also signed a new agreement with the U.S. Department of Energy to support its first reactor at Idaho National Laboratory.
• The stock rose 4.6% in premarket trading ahead of quarterly earnings due after the bell Tuesday.

Oklo scored a regulatory milestone on Tuesday, though it came with an asterisk. The company announced that the Nuclear Regulatory Commission has issued its first-ever materials license — not to Oklo itself, but to Atomic Alchemy, its wholly-owned subsidiary acquired in 2025.

Oklo Inc., OKLO

The license allows Atomic Alchemy to receive, store, process, and distribute isotopes at its Idaho Radiochemistry Laboratory in Idaho Falls. It specifically authorizes handling of up to 2 Curies of Ra-226, along with Co-60 and Am-241 for calibration purposes.

Isotopes like these are in growing demand across medicine, research, manufacturing, and defense. Oklo CEO Jacob DeWitte put it plainly: “Demand for critical isotopes is rising, but U.S. supply remains limited.”

The immediate commercial opportunity is real. Atomic Alchemy can now begin initial commercial sales from its Idaho lab, which marks the first time anything in Oklo’s business can generate revenue. The company remains pre-revenue overall.

One thing to be clear about: this is not the reactor license Wall Street has been watching for. Oklo’s advanced fast reactors are still working through the NRC approval process. Without that clearance, Oklo cannot sell electricity — its core long-term business.

What the License Actually Covers

The NRC granted the license after completing a review and an onsite inspection of the Idaho facility. Atomic Alchemy plans to recover and process disused radium sources — material that was previously treated as waste — and turn it into feedstock for medical isotope production, including targeted alpha therapy supply chains.

Longer term, the lab experience feeds into a bigger plan. Atomic Alchemy is developing a multi-reactor isotope foundry with up to four Versatile Isotope Production Reactor (VIPR) systems, each with around 15 MWth capacity.

Tuesday also brought a second piece of news. Oklo announced it had signed an agreement with the U.S. Department of Energy to support the design, construction, and operation of its first reactor at Idaho National Laboratory, under the DOE’s Reactor Pilot Program.

The Meta Partnership and Earnings Watch

Oklo’s nuclear ambitions have attracted a high-profile backer. The company has a partnership with Meta Platforms to build a nuclear campus in southeastern Ohio. BofA Securities described it as “one of a few firm, binding partnerships today” in the broader nuclear industry.

The stock was up 4.6% in premarket trading on Tuesday as investors digested the news. Oklo is scheduled to report quarterly earnings after market close the same day.

The company is targeting commercial nuclear power production by late 2027 or 2028.

The post Oklo Stock Jumps 5% as Subsidiary Clears First Regulatory Hurdle – Time to Buy? appeared first on CoinCentral.